10-Q: EBR Systems Reports Q2 2026 Results, Faces Going Concern Doubt

EBR Systems, Inc. reported increased net sales for Q2 2026, but also disclosed substantial doubt about its ability to continue as a going concern, despite FDA approval of its WiSE CRT System.

Summary

• EBR Systems, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026.
• The company reported net sales of $2.6 million for the three months ended June 30, 2026, a significant increase from $0.17 million in the same period of 2025.
• For the six months ended June 30, 2026, net sales were $5.0 million, up from $0.17 million in the prior year period.
• Despite increased sales, the company incurred a net loss of $17.5 million for the three months ended June 30, 2026, and $34.5 million for the six months ended June 30, 2026.
• The company has substantial doubt about its ability to continue as a going concern due to ongoing operating losses, negative cash flows, and significant debt obligations maturing within the next twelve months.
• EBR Systems received FDA approval for its WiSE CRT System in April 2025 and began commercialization in Q2 2025.
• The company completed several capital raises in June 2026, totaling approximately $75.8 million in net proceeds, to fund operations.
• A significant reverse stock split (1-for-10) was effective on April 1, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant net losses, negative cash flow from operations, and substantial doubt about the company's ability to continue as a going concern, despite recent FDA approval and increased sales.

Positives

• Net sales increased significantly to $2.6 million for Q2 2026 and $5.0 million for the first six months of 2026, compared to $0.17 million for both periods in 2025.
• The company received FDA approval for its WiSE CRT System in April 2025, enabling commercial distribution in the U.S.
• Commercial implants increased to 46 at 23 hospitals in the US during Q2 2026, and 87 at 29 hospitals in the US for the first six months of 2026.
• The company successfully raised approximately $75.8 million in net proceeds through various equity offerings in June 2026.
• The company was in compliance with its debt covenants as of June 30, 2026.

Negatives

• The company incurred a net loss of $17.5 million for Q2 2026 and $34.5 million for the first six months of 2026.
• Negative cash flows from operations were $37.4 million for the first six months of 2026.
• As of June 30, 2026, the company has $41.8 million in debt obligations due within the next twelve months.
• There is substantial doubt about the company's ability to continue as a going concern.
• Gross margin was 13.0% for Q2 2026 and 10.5% for the first six months of 2026, significantly lower than 50% in the prior year periods, partly due to the decreasing benefit of previously expensed inventory.
• Excluding the benefit of previously expensed inventory, the gross margin would be negative (-16.9% for Q2 2026 and -20.9% for the first six months of 2026).

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern within one year after the date the financial statements are issued.
• The company's ability to continue as a going concern is dependent on raising additional capital through equity or debt financing.
• The commercial potential of the WiSE CRT System is unproven and requires effective sales, marketing, manufacturing, and distribution strategies.
• The company faces intense competition from large, well-capitalized companies in the medical device industry.
• The company may not be able to secure additional financing on acceptable terms, or at all, which could negatively impact its ability to pursue business strategies.
• The company is subject to customary financial and reporting covenants under its loan agreement with Runway Growth Finance Corp.
• The company detected a cybersecurity incident on or around February 13, 2026, and while currently deemed not material, its evaluation and response are ongoing.

Future Outlook

The company expects to continue incurring net losses and negative operating cash flows in the foreseeable future. Its ability to continue as a going concern is dependent on raising additional capital. The company intends to make significant investments in its sales and marketing organization to drive adoption of the WiSE CRT System.

Management Comments

• "The growth of our business depends on our ability to successfully commercialize WiSE and gain wide acceptance of WiSE by continuing to make physicians and other hospital staff aware of the benefits of WiSE to generate increased demand and frequency of use and thus increase sales to our hospital customers."
• "Our ability to grow our business will also depend on our ability to expand our customer base in existing or new target markets."
• "We intend to make significant investments in our sales and marketing organization by increasing the number of U.S. sales representatives and expanding our international marketing programs to help facilitate further adoption among existing hospital accounts as well as broaden awareness of our products to new hospital accounts."
• "We may never recoup our investment in any WiSE CRT System development which would adversely affect our financial condition and our business and business prospects."

Industry Context

StockSavvy.ai notes that EBR Systems operates in the highly competitive medical device sector, specifically focusing on cardiac rhythm management. The recent FDA approval for its leadless WiSE CRT System is a significant milestone, addressing a key limitation of traditional CRT devices (leads). However, the company faces challenges in market adoption, sales force expansion, and competition from established players.

Comparison to Industry Standards

• The company's gross margin of 13.0% for Q2 2026 is significantly lower than typical gross margins for established medical device companies, which often exceed 60-70%. This is partly attributed to the use of previously expensed inventory.
• The substantial net losses and negative cash flow from operations are common for early-stage medical device companies post-commercialization, but the magnitude and the resulting going concern doubt are concerning.
• The company's cash burn rate of approximately $37.4 million for the first six months of 2026 is high relative to its current revenue, indicating a need for significant and sustained funding.
• The capital raise of approximately $75.8 million in net proceeds is substantial and necessary given the company's financial position, but the success of future funding rounds remains a key concern.

Legal Proceedings

• Management believes that the probability of a material loss with respect to any currently pending legal proceeding is remote.
• The company does not believe that there are any pending legal proceedings or other loss contingencies that will, either individually or in the aggregate, have a material adverse impact on its financial statements.

Related Party Transactions

• Host-Plus Pty Ltd and H.E.S.T. Australia Ltd., related parties of Dr. Chris Nave, a non-executive director, participated in the Retail Entitlement Offer.
• BCP3 Pty Ltd, a related party of Dr. Chris Nave, has an irrevocable commitment to purchase CDIs subject to shareholder approval.

Stakeholder Impact

• Shareholders: Dilution from recent capital raises, but also potential for future growth if the WiSE CRT System gains market traction. Significant risk due to going concern issues.
• Creditors: The company has substantial debt maturing within the next year, and its ability to refinance or repay is critical.
• Employees: Continued investment in sales and R&D may lead to job growth, but financial instability poses job security risks.
• Customers (Hospitals): Access to a novel leadless CRT technology, but potential concerns about the long-term viability of the supplier.

Next Steps

• Drive adoption of the WiSE CRT System at key, high-volume hospitals in the U.S.
• Expand international marketing programs and target select high-volume hospitals in markets outside the U.S.
• Increase the number of U.S. sales representatives.
• Conduct post-approval study for the WiSE CRT System.
• Seek shareholder approval for the Tranche 2 Institutional Placement on August 18, 2026.
• Refinance long-term debt obligations prior to their scheduled maturity date.

Key Dates

Recommendation

The company has achieved a significant regulatory milestone with FDA approval and is showing strong top-line growth. However, the persistent net losses, negative cash flow, and explicit statement of substantial doubt about its going concern status present significant risks. The recent capital raises provide a runway, but the path to profitability and sustainable operations remains uncertain. A 'hold' recommendation reflects the balance between the potential of the technology and the severe financial risks.

Keywords

medical device, cardiac resynchronization therapy, CRT, WiSE CRT System, FDA approval, commercialization, capital raise, going concern